外源性肽预防乳腺癌复发的有效性:24个月的监测结果
本文综述了乳腺癌复发和早期转移的发生现状，并提供了逃避肿瘤细胞全身免疫监视的主要分子和细胞机制。这项工作的重点是循环肿瘤细胞作为疾病不良预后的主要因素，以及将Camelyn Bio(外源性肽)纳入BC管理方案的结果。目的:研究外源性肽对乳腺癌临床进展的影响，并将其作为24个月内无病生存的标准。材料与方法:本研究纳入76例IIA期(T1N1M0, T2N0M0)行皮下根治性乳房切除术，保留皮肤和鼻-鼻腔复核。根据伦理委员会的建议，患者自行同意进行本研究。统计分析采用描述性统计和比较分析法。为比较各研究组的定性参数，采用卡方(Pearson)标准。对于定量参数，对分布的正态性进行初步评估，这是选择参数(t检验)或非参数标准(Wilconson秩和(Mann-Whitney检验))的基础。非复发生存率分析采用Kaplan-Meier法。使用STATA 12统计分析软件包进行分析。 Results: In the group of patients receiving exogenous peptides, there was a harmonization of immune homeostasis, manifested by increased immune surveillance over the tumor process involving activated T-lymphocytes, as well as increased expression of TNF-α and IL-12. The analysis of survival curves showed that the 24-month non-recurring survival rate of the patients in the main group was 0.918 (95% CI: 0.847-0.989), and in the comparison group -0.763 (0.628-0.898). That is, in the group of patients receiving Camelyn Bio, during the 24 months of observation there was a significant increase in non-recurring survival and a reduction in the risk of recurrence of tumors and metastases for the indicated period by 71.8%-Hazard ratio (95% CI) = 0.292 (0.094-0.907 ), p=0.046. Conclusion: The results of this work allow us to assume that the use of Camelyn Bio in patients with breast cancer leads to a significant improvement in the rate of disease-free survival in the 24-month period after surgical intervention.
利特维年科，科诺瓦连科，塔茨基，科诺瓦连科，阿波斯托洛夫
菜单